Literature DB >> 15834854

Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data.

Kari Swarztrauber1, Jane Anau, Dawn Peters.   

Abstract

Administrative databases have the potential to assess quality and cost of care for parkinsonism and Parkinson's disease. However, the validity of findings is limited by our understanding of how cases are identified. Patient records listing International Classification of Diseases, Version 9, Clinical Modification (ICD-9 CM) codes for parkinsonism (n = 2,076) and dopaminergic medications (n = 2,798) were pulled from fiscal years 1999 to 2001 for patients in the Pacific Northwest Veterans Administration. Samples of these records (n = 397) and records without these ICD-9 CM codes (n = 500) were reviewed, and clinical data were extracted. The accuracy of administrative data to identify and distinguish between Parkinson's disease and parkinsonism was calculated. A total of 37.9% of parkinsonism cases were detected using pharmacy data and ICD-9 CM codes compared to 18.7% by using ICD-9 CM codes alone. The ICD-9 CM code for paralysis agitans (332.0) did not distinguish between probable Parkinson's disease and other causes of parkinsonism, whereas the ICD-9 CM code for degenerative basal ganglia disorder (333.0) predicted having secondary parkinsonism (odds ratio [OR] = 5.0) as well as dopa-responsiveness in patients without secondary parkinsonism (OR = 4.5). Administrative data are limited in the ability to identify parkinsonism. The ICD-9 CM code, 332.0, which is generally considered the code to identify Parkinson's disease, did not distinguish between parkinsonism and Parkinson's disease. Copyright 2005 Movement Disorder Society

Entities:  

Mesh:

Year:  2005        PMID: 15834854     DOI: 10.1002/mds.20479

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  22 in total

1.  Reliability of administrative data for the identification of Parkinson's disease cohorts.

Authors:  Filippo Baldacci; Laura Policardo; Simone Rossi; Monica Ulivelli; Silvia Ramat; Enrico Grassi; Pasquale Palumbo; Fabio Giovannelli; Massimo Cincotta; Roberto Ceravolo; Sandro Sorbi; Paolo Francesconi; Ubaldo Bonuccelli
Journal:  Neurol Sci       Date:  2015-02-08       Impact factor: 3.307

Review 2.  Recommendations for optimal ICD codes to study neurologic conditions: a systematic review.

Authors:  Christine St Germaine-Smith; Amy Metcalfe; Tamara Pringsheim; Jodie Irene Roberts; Cynthia A Beck; Brenda R Hemmelgarn; Jane McChesney; Hude Quan; Nathalie Jette
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

3.  Validating the 8 CPCSSN case definitions for chronic disease surveillance in a primary care database of electronic health records.

Authors:  Tyler Williamson; Michael E Green; Richard Birtwhistle; Shahriar Khan; Stephanie Garies; Sabrina T Wong; Nandini Natarajan; Donna Manca; Neil Drummond
Journal:  Ann Fam Med       Date:  2014-07       Impact factor: 5.166

4.  High exposure compared with standard exposure to metoclopramide associated with a higher risk of parkinsonism: a nationwide population-based cohort study.

Authors:  Shin-Chia Tsai; Shiow-Yunn Sheu; Li-Nien Chien; Hsin-Chien Lee; Eunice Jia-Shiow Yuan; Rey-Yue Yuan
Journal:  Br J Clin Pharmacol       Date:  2018-06-19       Impact factor: 4.335

5.  Validation of secondary data sources to identify Parkinson disease against clinical diagnostic criteria.

Authors:  Samay Jain; Jayandra Himali; Alexa Beiser; Thanh G N Ton; Margaret Kelly-Hayes; Mary Lou Biggs; Joseph A C Delaney; Caterina Rosano; Sudha Seshadri; Samuel A Frank
Journal:  Am J Epidemiol       Date:  2014-12-29       Impact factor: 4.897

6.  Post hoc Parkinson's disease: identifying an uncommon disease in the Cardiovascular Health Study.

Authors:  T G Ton; S Jain; R Boudreau; E L Thacker; E S Strotmeyer; A B Newman; W T Longstreth; H Checkoway
Journal:  Neuroepidemiology       Date:  2010-09-24       Impact factor: 3.282

7.  Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment.

Authors:  Karen Curtin; Annette E Fleckenstein; Reid J Robison; Michael J Crookston; Ken R Smith; Glen R Hanson
Journal:  Drug Alcohol Depend       Date:  2014-11-16       Impact factor: 4.492

8.  Optimizing algorithms to identify Parkinson's disease cases within an administrative database.

Authors:  Nicholas R Szumski; Eric M Cheng
Journal:  Mov Disord       Date:  2009-01-15       Impact factor: 10.338

9.  Anticholinergic burden in Parkinson's disease inpatients.

Authors:  Unax Lertxundi; Arantxazu Isla; Maria Angeles Solinis; Saioa Domingo-Echaburu; Rafael Hernandez; Javier Peral-Aguirregoitia; Juan Medrano
Journal:  Eur J Clin Pharmacol       Date:  2015-08-09       Impact factor: 2.953

10.  Medicare capitation model, functional status, and multiple comorbidities: model accuracy.

Authors:  Katia Noyes; Hangsheng Liu; Helena Temkin-Greener
Journal:  Am J Manag Care       Date:  2008-10       Impact factor: 2.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.